Table 1.
Comparison of CFA between HTLV-I positive patients and negative patients
| HTLV-I positive patients (n = 18) | HTLV-I negative patients (n = 54) | P-value | |
|---|---|---|---|
| Pulmonary function tests | |||
| %VC (%) | 63·3 ± 13·8 | 71·3 ± 13·2 | P < 0·05 |
| %FEV1 (%) | 66·8 ± 10·2 | 74·1 ± 11·3 | P < 0·05 |
| %DLCO (%) | 50·8 ± 16·9 | 55·3 ± 15·2 | n.s. |
| Radiographic appearance | |||
| Visual score | 27·4 ± 12·9 | 20·3 ± 13·1 | P < 0·05 |
| Ratio of upper lobe involvement | 10/18 | 15/54 | P < 0·05 |
| Prevalence of traction brochiectasis and honeycombing change | 12/18 | 20/54 | P < 0·05 |
| BALF analysis | |||
| Total cell count (×105/µl) | 2·88 ± 1·99 | 2·91 ± 1·85 | n.s. |
| Macrophage (×105/µl) | 1·82 ± 1·66 | 1·36 ± 1·41 | n.s. |
| Lymphocyte (×105/µl) | 0·69 ± 0·44 | 0·61 ± 0·38 | n.s. |
| Neutrophile (×105/µl) | 0·13 ± 0·15 | 0·16 ± 0·21 | n.s. |
| Eosinophile (×105/µl) | 0·03 ± 0·06 | 0·03 ± 0·05 | n.s. |
| CD4+ lymphocytes(%) | 35·9 ± 10·1 | 35·8 ± 16·9 | n.s. |
| CD8+ lymphocytes (%) | 34·1 ± 20·1 | 33·5 ± 13·5 | n.s.. |
| CD4+/CD8+ | 1·49 ± 1·01 | 1·33 ± 1·36 | n.s. |
| CD3+ lymphocytes (%) | 92·3 ± 11·3 | 88·9 ± 12·5 | n.s. |
| CD3+/CD25+ (%) | 27·9 ± 16·4 | 18·9 ± 16·6 | P < 0·05 |
| MMP-2 (ng/ml) | 3·89 ± 1·99 | 2·58 ± 2·01 | P < 0·05 |
| MMP-9 (ng/ml) | 7·1 ± 10·9 | 5·29 ± 6·99 | n.s. |
| TIMP-1 (ng/ml) | 10·24 ± 9·97 | 11·43 ± 12·22 | n.s. |
| TIMP-2 (ng/ml) | 11·28 ± 5·22 | 9·67 ± 6·35 | n.s. |
| MIP-1α (pg/ml) | 29·7 ± 9·6 | 20·3 ± 12·2 | P < 0·01 |
| IP-10 (pg/ml) | 27·8 ± 10·2 | 20·2 ± 10·8 | P < 0·05 |
| MCP-1 (pg/ml) | 31·4 ± 12·3 | 34·3 ± 17·7 | n.s. |
| IL-8 (pg/ml) | 29·8 ± 18·6 | 28·7 ± 17·8 | n.s. |
| sICAM (pg/ml) | 104·5 ± 27·7 | 80·4 ± 30·4 | P < 0·01 |